Actinium Pharmaceuticals (ATNM) Competitors $1.40 +0.18 (+14.75%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsTrends ATNM vs. ACTU, CKPT, PBYI, CDTX, IPHA, ADAP, BMEA, FATE, STRO, and TCRXShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Actuate Therapeutics (ACTU), Checkpoint Therapeutics (CKPT), Puma Biotechnology (PBYI), Cidara Therapeutics (CDTX), Innate Pharma (IPHA), Adaptimmune Therapeutics (ADAP), Biomea Fusion (BMEA), Fate Therapeutics (FATE), Sutro Biopharma (STRO), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Actuate Therapeutics Checkpoint Therapeutics Puma Biotechnology Cidara Therapeutics Innate Pharma Adaptimmune Therapeutics Biomea Fusion Fate Therapeutics Sutro Biopharma TScan Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Do insiders & institutionals have more ownership in ACTU or ATNM? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ACTU or ATNM? Actinium Pharmaceuticals has a consensus target price of $7.40, indicating a potential upside of 428.57%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community favor ACTU or ATNM? Actinium Pharmaceuticals received 5 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/AActinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% Which has stronger earnings and valuation, ACTU or ATNM? Actuate Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/AActinium Pharmaceuticals$80K546.00-$48.82M-$1.39-1.01 Does the media favor ACTU or ATNM? In the previous week, Actuate Therapeutics' average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score. Company Overall Sentiment Actuate Therapeutics Neutral Actinium Pharmaceuticals Neutral Is ACTU or ATNM more profitable? Actuate Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Actinium Pharmaceuticals N/A -100.85%-47.89% SummaryActinium Pharmaceuticals beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$39.93M$6.37B$5.23B$19.35BDividend YieldN/A2.94%5.13%3.72%P/E Ratio-1.018.3083.3640.90Price / Sales546.00311.691,257.9117.06Price / CashN/A61.4443.8219.84Price / Book1.076.055.325.76Net Income-$48.82M$154.90M$122.78M$993.25M7 Day Performance9.37%-1.73%-0.20%3.25%1 Month Performance20.69%2.68%3.71%5.22%1 Year PerformanceN/A2.76%27.30%19.40% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.2222 of 5 stars$1.40+14.8%$7.40+428.6%N/A$39.93M$80,000.00-1.0130ACTUActuate TherapeuticsN/A$7.99-3.7%N/AN/A$156.06MN/A0.0010Positive NewsGap UpCKPTCheckpoint Therapeutics3.3398 of 5 stars$3.18+0.6%$12.00+277.4%+71.0%$155.29M$47,000.00-1.7310Short Interest ↑Positive NewsPBYIPuma Biotechnology4.1903 of 5 stars$3.15-4.8%$7.00+122.2%-40.4%$154.63M$243.57M6.56200CDTXCidara Therapeutics4.0797 of 5 stars$21.84-9.0%$32.20+47.4%+52.4%$153.91M$44.65M-0.8690Short Interest ↑Positive NewsIPHAInnate Pharma3.3093 of 5 stars$1.84+4.0%$11.50+525.0%-37.4%$152.36M$24.85M0.00220Analyst ForecastNews CoveragePositive NewsADAPAdaptimmune Therapeutics2.2992 of 5 stars$0.59-5.4%$2.79+375.0%-20.0%$150.15M$175.04M-2.67449Short Interest ↑News CoverageBMEABiomea Fusion2.9302 of 5 stars$4.14+4.0%$39.36+850.8%-72.5%$150.03MN/A-1.0350Analyst ForecastFATEFate Therapeutics4.6481 of 5 stars$1.30-11.3%$6.75+419.2%-71.1%$148.07M$13.45M-0.79550Short Interest ↓Positive NewsSTROSutro Biopharma4.4126 of 5 stars$1.79-3.5%$11.13+523.2%-51.1%$147.19M$160.96M-1.11240Short Interest ↑News CoverageGap UpTCRXTScan Therapeutics2.5696 of 5 stars$2.70-2.5%$11.25+316.7%-58.8%$144.10M$9.36M-2.55100News Coverage Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Checkpoint Therapeutics Alternatives Puma Biotechnology Alternatives Cidara Therapeutics Alternatives Innate Pharma Alternatives Adaptimmune Therapeutics Alternatives Biomea Fusion Alternatives Fate Therapeutics Alternatives Sutro Biopharma Alternatives TScan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ATNM) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
